-
公开(公告)号：US20220363775A1
公开(公告)日：2022-11-17
申请号：US17728183
申请日：2022-04-25
申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER , MILLENNIUM PHARMACEUTICALS, INC. , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
IPC分类号： C07K16/28 , C07K14/705 , C07K14/725 , A61P35/00 , A61K35/17 , A61P35/02
摘要： The presently disclosed subject matter provides for chimeric receptors that target ADGRE2 and chimeric receptors that target CLEC12A. The presently disclosed subject matter also provides for cells comprising the ADGRE2-targeted chimeric receptors, cells comprising the CLEC12A-targeted chimeric receptors, and cells comprising the ADGRE2-targeted chimeric receptors and the CLEC12A-targeted chimeric receptors. The presently disclosed subject matter further provides uses of such cells for treating tumors, e.g., AML.
-
公开(公告)号：US20220315660A1
公开(公告)日：2022-10-06
申请号：US17173716
申请日：2021-02-11
发明人： Renier J. Brentjens , Eric L. Smith , Chen Liu
IPC分类号： C07K16/28 , C07K14/705 , A61K47/68 , A61P35/00 , G01N33/68
摘要： The presently disclosed subject matter provides antibodies that bind to B-cell maturation antigen (BCMA) and methods of using the same.
-
公开(公告)号：US20220307031A1
公开(公告)日：2022-09-29
申请号：US17668504
申请日：2022-02-10
发明人： Jose Baselga , Eneda Toska , Scott Armstrong
IPC分类号： C12N15/113 , A61P35/00 , A61K31/4439 , A61K31/454 , A61K31/713 , A61K45/06
摘要： The presently disclosed subject matter relates to the administration of a KMT2D inhibitor for the treatment of a cancer. The present invention is based on the discovery that upon PI3K inhibition, KMT2D activity is upregulated, resulting in an increase in the expression of genes involved in breast cancer cell proliferation and tumor growth. Accordingly, the present invention provides methods for treating a subject that has cancer by administering a therapeutically effective amount of an KMT2D inhibitor.
-
公开(公告)号：US20220306986A1
公开(公告)日：2022-09-29
申请号：US17514742
申请日：2021-10-29
IPC分类号： C12N5/0735
摘要： The present disclosure provides highly efficient, non-invasive, and reversible methods for selectively enriching pluripotent cells (e.g., human pluripotent cells and mouse pluripotent cells) in a cell population using a glutamine-deficient medium. The presently disclosed methods have the advantageous of efficiently enriching pluripotent cells in a heterogenous cell population without altering the biological properties of any individual cells.
-
公开(公告)号：US11447572B2
公开(公告)日：2022-09-20
申请号：US16568152
申请日：2019-09-11
发明人： Jimmy Rotolo , Richard Kolesnick
摘要： Monoclonal antibodies directed to ceramide that inhibit apoptosis are disclosed. Humanized and scFv versions of the antibodies are also disclosed. Methods for prevention or treatment of apoptosis in a subject by administration of the anti-ceramide antibodies are disclosed.
-
公开(公告)号：US20220280538A1
公开(公告)日：2022-09-08
申请号：US17634775
申请日：2020-08-13
发明人： Scott LOWE , John P. MORRIS, IV , Scott E. MILLMAN , Lydia FINLEY
IPC分类号： A61K31/655 , A61P35/00 , A61K31/662 , A61K31/198 , A61K31/506 , A61K31/7068 , A61K31/517 , A61K31/513 , A61K31/4745 , A61K31/519 , A61K31/282 , A61K39/395 , A61K31/47 , A61K31/704 , A61K31/573 , C12N15/113
摘要： The present technology relates generally to methods and compositions for treating, preventing, and/or ameliorating p53-mutant cancers in a subject in need thereof, including acute myeloid leukemia (AML), pancreatic cancer, and liver cancer, by administration of a therapeutically effective amount of a 2-oxoglutarate dehydrogenase (OGDH) inhibitor.
-
公开(公告)号：US11433040B2
公开(公告)日：2022-09-06
申请号：US16614770
申请日：2018-05-18
发明人： Jonathan Goldberg , Elena Goldberg , Wenfu Ma
IPC分类号： A61K31/192 , A61K31/222 , A61K45/06 , A61P35/00
摘要： The present disclosure provides compositions and methods for modifying endoplasmic reticulum trafficking of proteins. Also disclosed herein are methods for treating cancer and/or enhancing cancer or viral immunotherapy in a subject by increasing the extracellular secretion levels of GRP94 in the subject. Such methods comprise administering to the subject an effective amount of 4-PBA and/or a 4-PBA analog selected from among methoxy-PBA, 3-PPA, 5-PVA, hydroxy-PPA, hydroxy-PBA, and tolyl-BA.
-
78.发明申请公开(公告)号：US20220267442A1
公开(公告)日：2022-08-25
申请号：US17626941
申请日：2020-07-17
摘要： The present disclosure provides fusion proteins that specifically inhibit transforming growth factor-β (TGF-β) signaling in CD4+ helper T cells, and engineered CD4+ helper T cells that are deficient in TGF-β signaling, to counteract tumor-induced immune tolerance and promote anti-tumor immunity. The fusion proteins and engineered CD4+ helper T cells of the present technology are useful in methods for treating cancer, and enhancing the efficacy of other therapeutic agents against refractory cancer cells.
-
公开(公告)号：US20220257599A1
公开(公告)日：2022-08-18
申请号：US17626370
申请日：2020-07-15
IPC分类号： A61K31/517 , A61K31/4709 , A61K45/06 , A61P35/00
摘要： The present technology is directed to methods useful in treating cancer, slowing growth of a tumor, reversing growth of a tumor, slowing growth of a neoplasm, reversing growth of a neoplasm, slowing proliferation of a neoplasm, and/or reversing proliferation of a neoplasm, for cancers, tumors, and neoplasms harboring a constitutively active variant of one or both of KRAS or HRAS, where the constitutively active variant is a gain of function mutation, a duplication, or a gene amplification.
-
公开(公告)号：US20220242967A1
公开(公告)日：2022-08-04
申请号：US17613580
申请日：2020-05-22
摘要： The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the Glypican-3 (GPC3) protein. The antibodies of the present technology are useful in methods for detecting and treating GPC3-associated cancers in a subject in need thereof.
-
-
-
-
-
-
-
-
-
搜索结果
1193 条记录 (耗时 0.027 秒)
